Remote Speech Analysis in HF Patients Undergoing Haemodialysis
A Non-Intervantional Study to Create a Patient Recordings and Clinical Database Using the Cordio System
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Jerusalem, Israel
- Hadassah Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients undergoing hemodialysis every 5-10 days in order to balance their volume overload.
- Class C Heart Failure patient with reduced EF CHF (EF<40%) and NYHA 2-3.
- Patients with dyspnea clinically related to pulmonary congestion
- Patient with more than 3 months HF disease duration.
- The patient is willing to participate as evidenced by signing the written informed consent.
- Male or non-pregnant female patient
Exclusion Criteria:
- Subject who, in the Investigator's opinion, unable to comply with the daily use of the App due to mental disorders (e.g., depression, dementia).
- Patient who has had a major cardiovascular event (e.g., myocardial infraction, stroke) within 3 months prior to screening visit.
- Patients likely to undergo heart transplantation/ LVAD within 6 months of Screening Visit or baseline functional capacity of NYHA 4.
- Patients with evidence of active Infection.
- Patient with severe alcohol or drug use.
- Psychological instability, inappropriate attitude or motivation.
- Patient with life threatening debilitating disease other than cardiac.
- Subject currently enrolled in another investigational device or drug trial that has not completed the primary endpoint or that clinically interferes with the current study endpoints.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Other
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
HF patients
HF patients will use the Cordio Medical app to record in their hospital visits and at home.
|
Recording to an app, no interference to the regular care
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of CHF patients with and without acute lung accumulation. in R&D Database
Time Frame: throughout study, upto 60 days per patient
|
The objective of the study is to create a recordings database of CHF patients with and without acute lung accumulation.
|
throughout study, upto 60 days per patient
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Ittamar Gork, Dr., Hadassah Ein Kerem
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CLN0014
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.